ICPOC 2026 Speaker Spotlight: Dr. Saba Beigh

The 2nd Edition of the International Cancer and Precision Oncology Conference (ICPOC2026) is pleased to welcome Dr. Saba Beigh, Associate Professor of Toxicology & Pharmacology at Al-Baha University, Saudi Arabia.

🎤 Presentation

Molecular Disruption of Pulmonary Surfactant Proteins by Airborne Pollutants: An Integrative In-Silico Toxicology Approach

🔬 Session Highlights

• Molecular impact of airborne pollutants on lung surfactant proteins
• In-silico toxicology for respiratory risk assessment
• Molecular docking and molecular dynamics simulations
• Mechanisms of pollutant-induced protein disruption
• Predicting respiratory toxicity using computational approaches
• Supporting environmental health and preventive strategies

👩‍🔬 About the Speaker

• Associate Professor of Toxicology & Pharmacology, Al-Baha University
• Ph.D. in Toxicology & Pharmacology, Jamia Hamdard University, India
• Postdoctoral Researcher in Nanotoxicology, University of Strasbourg, France
• Research expertise in pulmonary toxicology, nanotoxicology, oxidative stress, immunopharmacology, and computational pharmacology
• Recipient of the EUROTOX Best Poster Award and CSIR-SRF Fellowship

📅 November 23–25, 2026

📍 Singapore & Online

🌐 Website: https://cancer.miconferences.com/

📄 Abstract Submission: https://cancer.miconferences.com/abstract-submission

#ICPOC2026 #PulmonaryResearch #Toxicology #Nanotoxicology #EnvironmentalHealth #ComputationalBiology #RespiratoryMedicine #OncologyConference

ICPOC 2026 Speaker Spotlight: Dr. Ling Yin

The 2nd Edition of the International Cancer and Precision Oncology Conference (ICPOC 2026) proudly welcomes Dr. Ling Yin, Vice Dean, College of Life Sciences, Weifang Institute of Technology, China.

🎤 Presentation

Targeting Hspd1 Attenuates Neuroinflammation and Promotes Functional Recovery After Intracerebral Hemorrhage

🔬 Session Highlights

• Hspd1 as a novel therapeutic target
• Neuroinflammation and immune checkpoint regulation
• Microglial polarization in brain injury
• Transcriptomic and alternative splicing analysis
• Improved neurological recovery after intracerebral hemorrhage (ICH)
• Translational approaches in immunotherapy and neuroscience
  

👩‍🔬 About the Speaker

• Vice Dean, College of Life Sciences, Weifang Institute of Technology, China
• PhD from South China Agricultural University
• Postdoctoral training at Fudan University and the University of Florida College of Medicine
• Research expertise in cancer immunology, gene therapy, and neuroinflammation
• Editorial board member of multiple international journals
• Global Recognition Award Recipient (2024 & 2026)
• High-Caliber Talent of Hefei City

📅 November 23–25, 2026
📍 Singapore & Online

🌐 Website: https://cancer.miconferences.com/

📄 Abstract Submission: https://cancer.miconferences.com/abstract-submission

#ICPOC2026 #CancerResearch #Neuroinflammation #Immunotherapy #GeneTherapy #Neuroscience #PrecisionOncology #MedicalResearch

ICPOC 2026 Speaker Spotlight: Dr. Zheng Weihui

The 2ndEdition of the International Cancer and Precision Oncology Conference (ICPOC2026) is delighted to welcome Dr. Zheng Weihui, Associate Researcher at Zhejiang Cancer Hospital, China.

🗣 Presentation

The Association of Gene Mutation and Neck Lymph Node Metastasis in Patients with Medullary Thyroid Carcinoma

🔬 Session Highlights

• RET gene mutations and Medullary Thyroid Carcinoma (MTC)
• Next-Generation Sequencing (NGS) in precision oncology
• Association between RET mutations and lymph node metastasis
• Clinical significance of p.M918T and p.C618R/G mutations
• Predictive biomarkers for lateral neck lymph node metastasis
• Improving surgical planning and patient outcomes
• Precision medicine approaches for thyroid cancer

👩‍⚕️ About the Speaker

• Associate Researcher, Zhejiang Cancer Hospital, China
• Clinician specializing in thyroid and parathyroid surgery
• MD with postdoctoral training
• Master's Supervisor
• Young Healthcare Talent of Zhejiang Province
• Former Visiting Scholar at Singapore's A*STAR
• Research focus on recurrent laryngeal nerve preservation, parathyroid identification, and precision thyroid cancer surgery

📅 November 23–25, 2026
📍 Singapore & Online

🌐 Website: https://cancer.miconferences.com/

📄 Abstract Submission: https://cancer.miconferences.com/abstract-submission

#ICPOC2026 #ThyroidCancer #PrecisionOncology #CancerResearch #RETMutation #NGS #Oncology #SurgicalOncology

Dr. Dmitri Lapotko to Present Breakthrough Research on Plasmonic Nanobubbles at ICPOC 2026

The 2ndEdition of the International Cancer and Precision Oncology Conference (ICPOC2026) is pleased to welcome Dr. Dmitri Lapotko, Doctor of Science at Scorpido Photonics, Inc., United States, as a distinguished speaker.

An internationally recognized expert in biophotonics, nanotechnology, and plasmonics, Dr. Lapotko has pioneered innovative approaches that combine laser physics, engineering, and medicine to advance cancer diagnostics and treatment.

Presentation Title

Non-Stationary External Energy Mechanisms in Cancer Diagnostics and Treatment

About the Session

Cancer diagnosis and treatment are entering a new era where external energy, rather than conventional drugs alone, can be used to precisely identify and eliminate diseased cells.

In this groundbreaking presentation, Dr. Lapotko will introduce the science behind laser-generated plasmonic nanobubbles—microscopic energy events created within targeted cells that enable highly accurate diagnostics and therapeutic interventions.

By integrating physics, nanotechnology, and biology, this technology provides rapid, targeted, and minimally invasive solutions while reducing damage to healthy tissues.

Key Learning Points

• Understanding plasmonic nanobubbles and non-stationary plasmonics
• Laser-based cellular diagnostics and therapy
• Precision destruction of aggressive cancer cells
• Cell-level medicine powered by external energy
• Integration with artificial intelligence and robotics
• Applications in cancer diagnostics and biopsy
• Microsurgery, endoscopy, and targeted drug delivery
• Future directions for precision oncology

About Dr. Dmitri Lapotko

Dr. Dmitri Lapotko earned his M.S. in Thermal Physics and Ph.D. in Laser Defense Applications from Belarus State University, followed by a Doctor of Science in Bioengineering from the A.V. Lykov Heat and Mass Transfer Institute.

His pioneering research led to the invention of laser-generated plasmonic nanobubbles, establishing an entirely new platform for cancer diagnostics, therapy, microsurgery, and targeted drug delivery.

Dr. Lapotko's work has laid the scientific foundation for non-stationary plasmonics and nanophotonics, and his contributions are comprehensively presented in his book, "Plasmonic Nanobubbles: From Physics to Clinics."

His innovations continue to shape the future of precision medicine by enabling rapid, highly selective, and minimally invasive cancer treatments.

Join ICPOC 2026

ICPOC 2026 will unite leading researchers, clinicians, engineers, and industry experts to discuss the latest innovations in cancer research and precision oncology.

📅 Date: November 23–25, 2026

📍 Venue: Singapore & Online

🌐 Website: https://cancer.miconferences.com/

📄 Submit Your Abstract:
https://cancer.miconferences.com/abstract-submission

Be part of the global conversation driving the next generation of cancer diagnosis and treatment.

#ICPOC2026 #PrecisionOncology #CancerResearch #Nanotechnology #Biophotonics #Photonics #Nanomedicine #ArtificialIntelligence #CancerDiagnostics #MedicalInnovation

Dr. Tanja Obradovic to Speak at ICPOC 2026 on Strategic CRO Selection in Oncology Drug Development

The 2nd Edition of International Cancer and Precision Oncology Conference (ICPOC 2026) is delighted to welcome Dr. Tanja Obradovic, Strategy Consultant and internationally recognized oncology drug development expert, as a featured speaker.

With more than 20 years of experience in oncology pharmaceutical development, Dr. Obradovic has played a significant role in advancing innovative cancer therapies across multiple stages of clinical development.

Presentation Title

How to Choose the Right Clinical Research Organization (CRO) Partner When Developing aNew Cancer Drug While Meeting Challenges of Current Critical Trends in OncologyDrug Development

About the Session

The rapid advancement of immunotherapy, cell therapy, and gene therapy has transformed oncology drug development, creating new opportunities while introducing greater complexity in clinical research.

Selecting the right Clinical Research Organization (CRO) has become a critical strategic decision for biopharmaceutical companies seeking efficient clinical execution, regulatory compliance, and successful global development.

During her presentation, Dr. Obradovic will discuss practical strategies for identifying and evaluating CRO partners capable of supporting modern oncology clinical trials.

Key Learning Points

• Evaluating CRO expertise for oncology clinical trials
• Matching CRO capabilities with product development stages
• Meeting regulatory expectations for successful clinical development
• Assessing strategic execution, feasibility, and risk management
• Evaluating project management and quality systems
• Key considerations for oncology products entering the US market
• Determining the optimal timing for CRO engagement
• Best practices for selecting long-term strategic development partners

About Dr. Tanja Obradovic

Dr. Tanja Obradovic brings over two decades of leadership experience in oncology pharmaceutical development.

She held senior leadership roles at Merck, where she contributed extensively to the development, regulatory approvals, and lifecycle management of Keytruda across multiple cancer indications, including melanoma, lung cancer, and women's cancers.

She later led innovative drug and cell therapy development at Takeda before serving as Vice President of Drug Development Services and Scientific Affairs within Medical Strategy at ICON.

Currently, she serves as a Strategy Consultant and advises several biotechnology companies on oncology drug development and clinical strategy.

Join ICPOC 2026

ICPOC 2026 will bring together renowned scientists, clinicians, pharmaceutical leaders, and healthcare innovators to discuss the latest advances in cancer research and precision oncology.

📅 Date: November 23–25, 2026

📍 Venue: Singapore & Online

🌐 Website: https://cancer.miconferences.com/

📄 Submit Your Abstract:
https://cancer.miconferences.com/abstract-submission

Join us for three days of scientific excellence, collaboration, and innovation shaping the future of cancer care.

#ICPOC2026 #ClinicalResearch #CancerResearch #DrugDevelopment #ClinicalTrials #Oncology #PrecisionMedicine #Biopharma #CRO #Immunotherapy

Transforming Early Ovarian Cancer Detection with Advanced Biosensor Technology

🎤 Professor Michael Thompson

🏛 University of Toronto, Canada

🎙 Keynote Presentation

Presentation Title

Multiplexed Sensor-Based Detection of Biomarkers for Early-Stage Ovarian Cancer

Event

2nd Edition of International Cancer and Precision Oncology Conference (ICPOC 2026)

🔬 Advancing Precision Diagnostics Through Biosensor Innovation

Early diagnosis is one of the most important factors in improving survival rates for ovarian cancer patients. At ICPOC 2026, Professor Michael Thompson will present innovative research on multiplexed biosensor technologies designed to detect ovarian cancer biomarkers with greater sensitivity and precision.

His work combines cutting-edge biosensing approaches to simultaneously analyze multiple biomarkers, providing new opportunities for earlier diagnosis and more personalized clinical decision-making.

---

🔍 Key Highlights

✔ Multiplexed biosensor platforms for ovarian cancer

✔ Detection of CA125 and Lysophosphatidic Acid (LPA) biomarkers

✔ Ultra-high frequency acoustic wave sensing

✔ Iron oxide nanoparticle chemiluminescence technology

✔ Electrochemical biosensors using voltammetry

✔ High sensitivity for early-stage cancer detection

✔ Precision medicine applications

✔ Next-generation diagnostic technologies

This research demonstrates how biosensor innovation can improve early cancer diagnosis and contribute to more effective patient management.

---

👨‍🔬 About the Speaker

Professor Michael Thompson is Professor of Bioanalytical Chemistry at the University of Toronto, Canada, and is internationally recognized for pioneering research in biosensor technology.

Career Highlights

🏆 Professor of Bioanalytical Chemistry, University of Toronto

🏆 Pioneer in biosensor research and analytical chemistry

🏆 Robert Boyle Gold Medal – Royal Society of Chemistry

🏆 Elsevier Prize in Biosensor and Bioelectronics Technology

🏆 E.W.R. Steacie Award – Chemical Society of Canada

🏆 2023 Royal Society of Chemistry Horizons Prize in Analytical Science

🏆 International leader in protein surface chemistry, biosensors, and biomedical diagnostics

His research continues to drive advances in precision diagnostics and next-generation healthcare technologies.

---

🌍 Join ICPOC 2026

Meet global leaders in oncology, biosensors, precision medicine, and biomedical innovation.

📅 November 23–25, 2026

📍 Singapore & Online

🌐 Official Website
https://cancer.miconferences.com/

📄 Submit Abstract

https://cancer.miconferences.com/abstract-submission

#ICPOC2026 #OvarianCancer #Biosensors #CancerDiagnostics #PrecisionMedicine #CancerResearch #MedicalInnovation #BioanalyticalChemistry #OncologyConference

Advancing Deep Tumor Detection Through Confocal X-ray Fluorescence Imaging

🎤 Professor Rodolfo Gabriel Figueroa Saavedra

🏛 Universidad de La Frontera, Chile

🎙 Keynote Presentation

Presentation Title

Precise Deep Detection of Tumoral Biomarkers Using Large-Scale Confocal X-ray Fluorescence

Event

2nd Edition of International Cancer and Precision Oncology Conference (ICPOC 2026)

---

🔬 Revolutionizing Cancer Imaging with Advanced X-ray Fluorescence Technology

Early and accurate tumor detection remains one of the greatest challenges in modern oncology. At ICPOC 2026, Professor Rodolfo Gabriel Figueroa Saavedra will present pioneering research on large-scale confocal X-ray fluorescence (XRF) technology for the precise detection of deep-seated tumor biomarkers.

His work introduces an innovative imaging platform designed to improve molecular imaging and support future image-guided cancer therapies through advanced theranostic technologies.

🔍 Key Highlights

✔ Large-scale Confocal X-ray Fluorescence (XRF)

✔ Deep detection of tumor biomarkers up to 15 cm

✔ Gadolinium-based biomarker imaging

✔ Low-dose imaging with rapid acquisition

✔ Improved signal-to-background ratio

✔ Real-time molecular imaging

✔ COXIRIS theranostic platform

✔ Patented and patent-pending technologies

The presented research demonstrates the potential of confocal XRF systems to enhance cancer diagnosis and pave the way for next-generation image-guided precision oncology.

---

👨‍🔬 About the Speaker

Professor Rodolfo Gabriel Figueroa Saavedra is a distinguished Radiation Physicist and Full Professor at Universidad de La Frontera, Chile.

Career Highlights

🏆 Director, Centro de Excelencia de Física e Ingeniería en Salud

🏆 Founder of Chile's first Master's Program in Medical Physics

🏆 Inventor of CONVERAY and COXIRIS technologies

🏆 Approximately 24 patents

🏆 Around 100 scientific publications

🏆 Internationally recognized expert in medical physics, radiation sciences, theranostics, and biomedical engineering

His groundbreaking research is driving innovation in cancer detection, radiotherapy, and molecular imaging technologies.

---

🌍 Join ICPOC 2026

Discover the latest advances in precision oncology, cancer imaging, and translational research at ICPOC 2026.

📅 November 23–25, 2026

📍 Singapore & Online

🌐 Official Website
https://cancer.miconferences.com/

📝 Register
https://cancer.miconferences.com/register

📄 Submit Abstract
https://cancer.miconferences.com/abstract-submission

#ICPOC2026 #MedicalPhysics #CancerImaging #Theranostics #XRF #MolecularImaging #PrecisionOncology #CancerResearch #BiomedicalEngineering